Cornish businessman scoops Topra award

Jonathan Trethowan wins Inspiration category

Jonathan Trethowan, director of regulatory affairs company Trac Services, based in Camborne, Cornwall, UK, has taken top honours in the Inspiration category at the Topra Symposium (the organisation representing regulatory affairs professionals).

A panel of five judges awarded Trethowan the honour at the awards, which recognise excellence within the industry, after he was nominated by Trac’s regulatory affairs executive, Lisa Pascoe.

Trethowan set up the company with his wife Sarah in 2001 and has seen it grow to work with UK and European pharmaceutical companies, ensuring that they are in compliance with the latest regulations concerned with the manufacture and marketing of medicines.

‘I am absolutely delighted to have won the Inspiration Award – it is a fantastic honour and to be honest I was thrilled just to be nominated,’ said Trethowan.

Pascoe added: ‘Over the past five years Jonathan has developed an excellent in-house training programme that has helped coach and support myself and six other graduates to become experienced regulatory professionals in our own right.

‘In addition, he also participates in a TOPRA working party that is identifying future approaches to professional development; I think his involvement at TRAC and within the industry as a whole shows his passion and commitment.’

You may also like

Packaging

Amarox recalls sertraline batch after citalopram blister strips found inside sealed cartons

The MHRA has issued a class two recall of one batch of Amarox's sertraline 100 mg film-coated tablets following a secondary packaging error that resulted in citalopram 40 mg blister strips being included in sealed cartons
Regulatory

MHRA report shows agency met targets and closed year in financial surplus

The UK government agency has reported meeting or exceeding every statutory performance target in the 2025/26 financial year, closing in financial surplus while advancing clinical trials reform and AI regulation
Regulatory

FDA approves AstraZeneca's Breztri Aerosphere as first single-inhaler triple therapy for asthma

AstraZeneca has received FDA approval to extend Breztri Aerosphere's indication to include maintenance treatment of asthma in patients aged 12 and older, based on Phase III KALOS and LOGOS trial data showing statistically significant improvements in lung function
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Regulatory

FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus

AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Subscribe now